Citigroup Inc Catalyst Pharmaceuticals, Inc. Transaction History
Citigroup Inc
- $190 Billion
- Q1 2025
A detailed history of Citigroup Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 252,388 shares of CPRX stock, worth $6.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
252,388
Previous 219,734
14.86%
Holding current value
$6.4 Million
Previous $4.59 Million
33.48%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding CPRX
# of Institutions
389Shares Held
99.3MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$474 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$215 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$140 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$86.8 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$79.5 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.61B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...